Roche Breaks Into Bladder Cancer, But Merck Is Hot On Its Heels
Executive Summary
Roche leads the way in bladder cancer, with a strong response rate in a Phase Ib study and “breakthrough therapy” status. But Merck says that it has “very good” undisclosed data in-house and plans to kick off a full registration program soon.